DK141682B - Fremgangsmåde til ultrafiltrering af opløsninger, der indeholder geldannende dispergerede partikler eller geldannende makromolekyler. - Google Patents

Fremgangsmåde til ultrafiltrering af opløsninger, der indeholder geldannende dispergerede partikler eller geldannende makromolekyler. Download PDF

Info

Publication number
DK141682B
DK141682B DK53170AA DK53170A DK141682B DK 141682 B DK141682 B DK 141682B DK 53170A A DK53170A A DK 53170AA DK 53170 A DK53170 A DK 53170A DK 141682 B DK141682 B DK 141682B
Authority
DK
Denmark
Prior art keywords
membrane
gelling
ultrafiltration
macromolecules
solute
Prior art date
Application number
DK53170AA
Other languages
Danish (da)
English (en)
Other versions
DK141682C (cg-RX-API-DMAC7.html
Inventor
Heinrich Strathmann
Richard William Baker
Original Assignee
Amicon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicon Corp filed Critical Amicon Corp
Publication of DK141682B publication Critical patent/DK141682B/da
Application granted granted Critical
Publication of DK141682C publication Critical patent/DK141682C/da

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/18—Apparatus therefor

Landscapes

  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
DK53170AA 1969-02-05 1970-02-03 Fremgangsmåde til ultrafiltrering af opløsninger, der indeholder geldannende dispergerede partikler eller geldannende makromolekyler. DK141682B (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79692869A 1969-02-05 1969-02-05
US79692869 1969-02-05

Publications (2)

Publication Number Publication Date
DK141682B true DK141682B (da) 1980-05-27
DK141682C DK141682C (cg-RX-API-DMAC7.html) 1980-10-20

Family

ID=25169415

Family Applications (1)

Application Number Title Priority Date Filing Date
DK53170AA DK141682B (da) 1969-02-05 1970-02-03 Fremgangsmåde til ultrafiltrering af opløsninger, der indeholder geldannende dispergerede partikler eller geldannende makromolekyler.

Country Status (10)

Country Link
US (1) US3541005A (cg-RX-API-DMAC7.html)
JP (1) JPS4931431B1 (cg-RX-API-DMAC7.html)
BE (1) BE745442A (cg-RX-API-DMAC7.html)
DE (1) DE2005260A1 (cg-RX-API-DMAC7.html)
DK (1) DK141682B (cg-RX-API-DMAC7.html)
FR (1) FR2033961A5 (cg-RX-API-DMAC7.html)
GB (1) GB1307331A (cg-RX-API-DMAC7.html)
NL (1) NL7001662A (cg-RX-API-DMAC7.html)
SE (1) SE350702B (cg-RX-API-DMAC7.html)
ZA (1) ZA70548B (cg-RX-API-DMAC7.html)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2254860C3 (de) * 1971-11-26 1984-03-29 Heinrich Frings Gmbh & Co Kg, 5300 Bonn Ultrafiltrationsverfahren für Flüssigkeiten, die Mikroorganismen, Makromoleküle oder andere kleine Feststoffteilchen enthalten
JPS568476U (cg-RX-API-DMAC7.html) * 1979-06-30 1981-01-24
JPS56110625A (en) * 1980-02-05 1981-09-01 Takeda Chem Ind Ltd Separating method of blood plasma and apparatus for the same
US4735726A (en) * 1981-07-22 1988-04-05 E. I. Du Pont De Nemours And Company Plasmapheresis by reciprocatory pulsatile filtration
US4640776A (en) * 1982-02-16 1987-02-03 E. I. Du Pont De Nemours And Company Plasmapheresis filtration module having pressure balancing and sealing means
US4639317A (en) * 1982-02-16 1987-01-27 E. I. Du Pont De Nemours And Company Plasmapheresis filtration module having improved sealing means
US4636312A (en) * 1982-02-16 1987-01-13 E. I. Du Pont De Nemours And Company Plasmapheresis filtration module having improved end plate
US4769150A (en) * 1982-02-16 1988-09-06 E. I. Du Pont De Nemours And Company Method and apparatus for plasmapheresis by reciprocatory pulsatile filtration
DE3525668A1 (de) * 1984-10-31 1986-05-07 Kernforschungsanlage Jülich GmbH, 5170 Jülich Verfahren zur bestimmung des gehaltes an in einem loesungsmittel geloesten stoffen
US4693886A (en) * 1985-04-22 1987-09-15 Alza Corporation Osmotic device with inert core
US5340590A (en) * 1987-06-25 1994-08-23 Alza Corporation Delivery system with bilayer osmotic engine
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US4969884A (en) * 1988-12-28 1990-11-13 Alza Corporation Osmotically driven syringe
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5035897A (en) * 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs
US4986918A (en) * 1989-11-08 1991-01-22 Romicon Inc. Membrane separation system and method of operation
US5030216A (en) * 1989-12-15 1991-07-09 Alza Corporation Osmotically driven syringe
US5474785A (en) * 1990-01-24 1995-12-12 Alza Corporation Delivery system comprising means for controlling internal pressure
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5240713A (en) * 1991-09-27 1993-08-31 Alza Corporation Dual rate agent delivery device
US5200194A (en) * 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy
US5540665A (en) * 1994-01-31 1996-07-30 Alza Corporation Gas driven dispensing device and gas generating engine therefor
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
EP0749038A1 (en) 1995-06-16 1996-12-18 Minnesota Mining And Manufacturing Company Light-sensitive photographic materials comprising tabular silver halide grains and azodicarbonamide derivatives
US6110499A (en) * 1997-07-24 2000-08-29 Alza Corporation Phenytoin therapy
US6514530B2 (en) 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
DK1035834T3 (da) 1997-12-05 2002-07-08 Alza Corp Osmotisk doseringsform omfattende en første og anden coating
HU226730B1 (en) 1997-12-22 2009-08-28 Euro Celtique Sa Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrextone
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US6174547B1 (en) 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
GB9822854D0 (en) 1998-10-21 1998-12-16 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
CN1325301A (zh) 1998-11-02 2001-12-05 阿尔扎有限公司 活性物质的控制释放
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6319510B1 (en) 1999-04-20 2001-11-20 Alayne Yates Gum pad for delivery of medication to mucosal tissues
EP1239840B1 (en) * 1999-12-09 2005-04-06 Alza Corporation Antiviral medication
CN103690540A (zh) 2000-10-30 2014-04-02 欧罗赛铁克股份有限公司 控释氢可酮制剂
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
MXPA04000584A (es) 2001-07-18 2004-04-20 Euro Celtique Sa COMBINACIONES FARMACeUTICAS DE OXICODONA Y NALOXONA.
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
AU2002357935A1 (en) * 2001-12-18 2003-06-30 Alza Corporation Dosage form for providing time-varying patterns of drug delivery
EP1465592A2 (en) * 2001-12-19 2004-10-13 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
AU2002357930B2 (en) * 2001-12-19 2007-06-28 Alza Corporation Formulation & dosage form for the controlled delivery of therapeutic agents
RU2295344C2 (ru) 2002-04-05 2007-03-20 Еуро-Селтик С.А. Фармацевтический препарат, содержащий оксикодон и налоксон
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
CN1665482A (zh) * 2002-04-29 2005-09-07 阿尔扎公司 羟可待酮控制输送给药的方法和剂型
PL372797A1 (en) * 2002-05-31 2005-08-08 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
US20050175697A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms of topiramate
US20050175690A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
EP1534238A1 (en) * 2002-07-29 2005-06-01 ALZA Corporation Formulations and dosage forms for controlled delivery of topiramate
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
DE60313359T2 (de) * 2002-12-17 2008-01-03 Abbott Gmbh & Co. Kg Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
WO2004064772A2 (en) * 2003-01-14 2004-08-05 Alza Corporation Methods and dosage forms with modified viscosity layers
DE602004015246D1 (de) * 2003-02-11 2008-09-04 Alza Corp Verfahren und dosierformen mit modifizierter schichtgeometrie
EP1905435A3 (en) 2003-03-11 2008-05-14 Euro-Celtique S.A. Titration dosing regimen for controlled release tramadol
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
AU2004249295A1 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating HIV
AU2004264316A1 (en) * 2003-08-06 2005-02-24 Alza Corporation Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
JP2007503389A (ja) * 2003-08-22 2007-02-22 アルザ・コーポレーシヨン 長期間にわたるトピラメートの段階的送達
AU2004268661A1 (en) * 2003-09-02 2005-03-10 Alza Corporation Novel drug compositions and dosage forms of topiramate
PL1663229T3 (pl) 2003-09-25 2010-09-30 Euro Celtique Sa Farmaceutyczne kombinacje hydrokodonu i naltreksonu
JP2007506775A (ja) * 2003-09-26 2007-03-22 アルザ・コーポレーシヨン 漸増する放出速度を表す制御放出製剤
AU2004314693B2 (en) 2003-09-26 2011-04-07 Alza Corporation Drug coating providing high drug loading and methods for providing the same
AU2004275816A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
CA2545834A1 (en) * 2003-11-14 2005-06-02 Alza Corporation Controlled release of topiramate in liquid dosage forms
US20050158365A1 (en) * 2003-12-22 2005-07-21 David Watson Drug delivery device with mechanical locking mechanism
US20050136095A1 (en) * 2003-12-22 2005-06-23 Brian Levy Drug delivery device with suture ring
EP1703894A1 (en) * 2003-12-23 2006-09-27 ALZA Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US20060009425A1 (en) * 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1765292B1 (en) 2004-06-12 2017-10-04 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US20050287213A1 (en) * 2004-06-28 2005-12-29 Wong Patrick S Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents
WO2006007351A2 (en) * 2004-06-28 2006-01-19 Alza Corporation Squeeze controlled oral dosage form
WO2006007354A2 (en) * 2004-06-28 2006-01-19 Alza Corporation A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device
WO2006023286A2 (en) * 2004-08-19 2006-03-02 Alza Corporation Controlled release nanoparticle active agent formulation dosage forms and methods
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006039459A1 (en) * 2004-09-30 2006-04-13 Bausch & Lomb Incorporated Capsule for encasing tablets for surgical insertion into the human body
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
PT2486942T (pt) 2004-11-24 2019-01-18 Meda Pharmaceuticals Inc Composições que compreendem azelastina e seus métodos de utilização
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US20060134162A1 (en) * 2004-12-16 2006-06-22 Larson Christopher W Methods for fabricating a drug delivery device
US20060165798A1 (en) * 2005-01-27 2006-07-27 Edgren David E Oral osmotic dosage form having a high flux membrane
BRPI0606339A2 (pt) * 2005-01-28 2009-06-16 Euro Celtique Sa formas farmacêuticas resistentes a álcool
US8318210B2 (en) * 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
US20060233882A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Osmotic dosage form
US20060257484A1 (en) * 2005-04-19 2006-11-16 Hwang Stephen S Combination of tramadol and substances that comprise gabapentin
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
CA2674039A1 (en) * 2006-12-28 2008-07-17 Astellas Pharma Inc. Sustained release formulation for tacrolimus
US8524749B2 (en) * 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
US8895061B2 (en) * 2007-03-02 2014-11-25 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
EP2164631A4 (en) * 2007-05-30 2013-08-21 Neos Therapeutics Lp MODIFICATION OF DRUG RELIEF IN SUSPENSIONS OF IONIC RESIN SYSTEMS
US20090087484A1 (en) * 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
JP5886632B2 (ja) 2009-03-10 2016-03-16 ユーロ−セルティーク エス．エイ． オキシコドンおよびナロキソンを含む即時放出医薬組成物
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
JP5849947B2 (ja) 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
PE20141132A1 (es) 2010-12-22 2014-09-19 Purdue Pharma Lp Formas de dosis de liberacion controlada encerradas resistentes a manipulaciones indebidas
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
CN104470928B (zh) 2012-07-16 2017-08-11 罗德科技公司 用于改进的阿片样物质合成的方法
TW201639855A (zh) 2012-07-16 2016-11-16 羅德科技公司 改良之類鴉片合成方法
EP2914255B1 (en) 2012-11-02 2021-07-21 Murray & Poole Enterprises, Ltd. Treatment or prevention of cardiovascular events via the administration of colchicine
JP6208261B2 (ja) 2013-02-05 2017-10-04 パーデュー、ファーマ、リミテッド、パートナーシップＰｕｒｄｕｅ Ｐｈａｒｍａ Ｌ．Ｐ． タンパリング抵抗性医薬製剤
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA2909370A1 (en) 2013-04-16 2014-10-23 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
US9855245B2 (en) 2013-04-30 2018-01-02 Abbvie Inc. Methods for improving lipid profiles using atrasentan
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
ES2672795T3 (es) 2014-01-15 2018-06-18 Rhodes Technologies Proceso para la síntesis mejorada de oximorfona
EP3094634A1 (en) 2014-01-15 2016-11-23 Rhodes Technologies Process for improved oxycodone synthesis
EP3258914A1 (en) 2015-02-20 2017-12-27 Osmotica Kereskedelmi ES Szolgaltato KFT Controlled release oral dosage form of gaba receptor agonist
EP3061501A1 (en) 2015-02-27 2016-08-31 Rottapharm Ltd. Composition for the treatment of acne
EP3998066A1 (en) 2015-04-17 2022-05-18 Murray And Poole Enterprises Limited Colchicine salicylate and uses thereof
EP3117825A1 (en) 2015-07-16 2017-01-18 Rottapharm S.p.A. Oral formulation comprising berberine and morus alba extract
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
JP2022514997A (ja) 2018-02-02 2022-02-17 マリー アンド プール エンタープライゼズ，リミテッド 腫瘍の増殖及び転移を阻害するためのコルヒチンの使用
JPWO2021029020A1 (cg-RX-API-DMAC7.html) 2019-08-13 2021-02-18
WO2021089715A1 (en) 2019-11-06 2021-05-14 Murray And Poole Enterprises, Ltd. Use of colchicine in the treatment and prevention of lung cancer
PE20230852A1 (es) 2020-06-10 2023-05-29 Auspex Pharmaceuticals Inc Formas farmaceuticas osmoticas que comprenden deutetrabenazina y metodos de uso de las mismas
IL317235A (en) 2022-06-08 2025-01-01 Auspex Pharmaceuticals Inc Osmotic dosage forms comprising ditetrabenzene and methods of using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3211645A (en) * 1962-07-17 1965-10-12 Technicon Instr Method and apparatus for filtering sanguineous liquid streams
US3305097A (en) * 1963-05-27 1967-02-21 Scientific Industries High pressure peristaltic pump for separation apparatus

Also Published As

Publication number Publication date
BE745442A (fr) 1970-07-16
ZA70548B (en) 1971-08-25
JPS4931431B1 (cg-RX-API-DMAC7.html) 1974-08-21
SE350702B (cg-RX-API-DMAC7.html) 1972-11-06
US3541005A (en) 1970-11-17
GB1307331A (en) 1973-02-21
DK141682C (cg-RX-API-DMAC7.html) 1980-10-20
DE2005260A1 (de) 1970-10-29
FR2033961A5 (cg-RX-API-DMAC7.html) 1970-12-04
NL7001662A (cg-RX-API-DMAC7.html) 1970-08-07

Similar Documents

Publication Publication Date Title
DK141682B (da) Fremgangsmåde til ultrafiltrering af opløsninger, der indeholder geldannende dispergerede partikler eller geldannende makromolekyler.
Drioli et al. Membrane distillataion in the treatment of aqueous solutions
Riley et al. Preparation of ultrathin reverse osmosis membranes and the attainment of theoretical salt rejection
Strathmann Membrane separation processes
US5098575A (en) Method and apparatus for processing liquid solutions of suspensions particularly useful in the desalination of saline water
Goldsmith Macromolecular ultrafiltration with microporous membranes
Wang et al. The characterization of flat composite nanofiltration membranes and their applications in the separation of Cephalexin
Nabetani et al. Effects of osmotic pressure and adsorption on ultrafiltration of ovalbumin
US4781837A (en) Method of performing osmetic distillation
US3133137A (en) High flow porous membranes for separating water from saline solutions
US3133132A (en) High flow porous membranes for separating water from saline solutions
Michaels et al. Ultrafiltration
Drioli et al. Microporous membranes in membrane distillation
Onsekizoglu Bagci Potential of membrane distillation for production of high quality fruit juice concentrate
de Pinho et al. Introduction in membrane technologies
CHERYAN Mass transfer characteristics of hollow fiber ultrafiltration of soy protein systems
Gupta et al. Characterization of nanofiltration and reverse osmosis membrane performance for aqueous salt solutions using irreversible thermodynamics
US3250701A (en) Stabilization of desalination membranes
Fernandez et al. Cross flow filtration of RNA extracts by hollow fiber membrane
JPS6362504A (ja) 有機成分含有水溶液中の有機成分の濃縮方法
Belhocine et al. Optimization of plasma proteins concentration by ultrafiltration
Tomaszewska Membrane distillation
Gabino et al. Evaluation of the cleaning of a new hydrophobic membrane for osmotic evaporation
US3544455A (en) Itaconic acid purification process using reverse osmosis
Do et al. A theory of limiting flux in a stirred batch cell